A new way to target #pancreatic #cancer: daraxonrasib uses cyclophilin A to block active #RAS. A recent trial found median overall survival of 13.2 versus 6.6 months with #chemotherapy in previously treated RAS G12-mutant patients.π
@ccboffice.bsky.social
link.springer.com/article/10.1...
